Comparing Haemonetics (HAE) & Cryolife (CRY)

Haemonetics (NYSE: HAE) and Cryolife (NYSE:CRY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Valuation & Earnings

This table compares Haemonetics and Cryolife’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Haemonetics $886.12 million 3.84 -$26.26 million $0.08 804.98
Cryolife $180.38 million 3.40 $10.77 million $0.28 65.54

Cryolife has lower revenue, but higher earnings than Haemonetics. Cryolife is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Haemonetics and Cryolife, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Haemonetics 0 2 4 0 2.67
Cryolife 0 0 4 0 3.00

Haemonetics presently has a consensus target price of $56.60, suggesting a potential downside of 12.10%. Cryolife has a consensus target price of $23.63, suggesting a potential upside of 28.75%. Given Cryolife’s stronger consensus rating and higher possible upside, analysts plainly believe Cryolife is more favorable than Haemonetics.


This table compares Haemonetics and Cryolife’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Haemonetics 0.50% 11.16% 6.79%
Cryolife 5.28% 6.43% 4.33%

Institutional & Insider Ownership

73.3% of Cryolife shares are held by institutional investors. 1.2% of Haemonetics shares are held by insiders. Comparatively, 6.0% of Cryolife shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Haemonetics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Cryolife has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.


Cryolife beats Haemonetics on 7 of the 13 factors compared between the two stocks.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Cryolife Company Profile

CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc. valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix. PhotoFix is a pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. The Preservation Services segment includes external services, such as preservation of cardiac and vascular tissues. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch, both of which are processed using CryoLife’s SynerGraft technology.

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with's FREE daily email newsletter.

Leave a Reply